Antiviral effects of Cacicol®, a heparan sulfate biomimetic for corneal regeneration therapy, for herpes simplex virus type-1 and varicella zoster virus infection
- 1 November 2017
- journal article
- research article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 23 (8) , 665-675
Abstract
Background: Cacicol®, a topical eye biopolymer containing a poly-carboxymethylglucose sulfate solution that is a regenerating matrix therapy agent, intended for wound healing of persistent corneal epithelial defects. Based on the chemical composition, we hypothesized that Cacicol® may compete with natural heparan sulfate (HS) which initiates cell surface attachment of herpes simplex virus type-1 (HSV-1), varicella zoster virus (VZV) and human adenovirus (HAdV), three viruses associated with corneal infections. Methods: Cacicol® was compared to vehicle in the following viral strains: HSV-1 SC16 strain and HSV-1 PSLR, a clinical isolate highly resistant to acyclovir and foscarnet; VZV ATH and VZV FLO, two VZV clinical isolates; and HAdV-D37 strain. Viruses in Cacicol® or vehicle were added to cells for 1 h during adsorption then viral replication was assessed by plaque reduction assays on Vero cells for HSV-1 and MeWo cells for VZV and by immunostaining assay on Hep-2 cells for HAdV-D37. Results: The vehicle had no effect, dose-dependent effects were demonstrated when HSV-1 SC16, HSV-1 PSLR, VZV ATH and VZV FLO were inoculated in the presence of Cacicol®, inhibiting viral replication by 98.4%, 98.9%, 90.1% and 89.0%, respectively. Cacicol® had no antiviral effect against HAdV-D37. Conclusions: Cacicol® has a significant antiviral activity on HSV-1 and VZV, but not on HAdV-D37. The lack of effect on HAdV is probably because it is less dependent on HS interactions for cell entry. Clinical studies are necessary to determine Cacicol® for an adjunct or alternative therapy of corneal HSV-1 or VZV infection, particularly for the management of antiviral resistant HSV-1.Keywords
This publication has 48 references indexed in Scilit:
- Topical Treatment with a New Matrix Therapy Agent (RGTA) for the Treatment of Corneal Neurotrophic UlcersInvestigative Ophthalmology & Visual Science, 2012
- Analysis of Human Adenovirus Type 19 Associated with Epidemic Keratoconjunctivitis and its Reclassification as Adenovirus Type 64Investigative Ophthalmology & Visual Science, 2012
- Anti-heparan Sulfate Peptides That Block Herpes Simplex Virus Infection in VivoJournal of Biological Chemistry, 2011
- Regenerating matrix-based therapy for chronic wound healing: a prospective within-subject pilot studyInternational Wound Journal, 2010
- A Double-Blind Placebo-Controlled Study to Evaluate Valacyclovir Alone and with Aspirin for Asymptomatic HSV-1 DNA Shedding in Human Tears and SalivaInvestigative Ophthalmology & Visual Science, 2009
- Role of Cellular Heparan Sulfate Proteoglycans in Infection of Human Adenovirus Serotype 3 and 35PLOS Pathogens, 2008
- Anterior Segment Complications of Herpes Zoster OphthalmicusOphthalmology, 2008
- Role for 3- O -Sulfated Heparan Sulfate as the Receptor for Herpes Simplex Virus Type 1 Entry into Primary Human Corneal FibroblastsJournal of Virology, 2006
- Application of FGF-2 to Modulate Herpetic Stromal KeratitisCurrent Eye Research, 2006
- Membrane Cofactor Protein Is a Receptor for Adenoviruses Associated with Epidemic KeratoconjunctivitisJournal of Virology, 2004